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Abstract
C22H29BrN2OS, triclinic, P1¯ (no. 2), a= 7.1722(3) Å,
b= 10.2350(4) Å, c= 14.8756(6) Å, α= 73.607(2)°,
β= 84.7020(10)°, γ= 88.7210(10)°, V = 1043.11(7) Å3, Z= 2,
Rgt(F)=0.0467, wRref(F2)=0.0870, T= 296(2) K.
CCDC no.: 1554481
The molecular structure is shown in the figure. Table 1 con-
tains crystallographic data and Table 2 contains the list of
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Table 1: Data collection and handling.
Crystal: Colourless block
Size: 0.44×0.15×0.11 mm
Wavelength: Mo Kα radiation (0.71073 Å)
µ: 2.09 mm−1
Diffractometer, scan mode: Bruker APEX-II, φ and ω
θmax, completeness: 33.8°,>99%
N(hkl)measured, N(hkl)unique, Rint: 29518, 8337, 0.066
Criterion for Iobs, N(hkl)gt: Iobs > 2 σ(Iobs), 5322
N(param)refined: 244
Programs: Bruker [1], SHELX [2, 3],
WinGX/ORTEP [4]
the atoms including atomic coordinates and displacement
parameters.
Source of material
4-Bromobenzyl bromide (500 mg, 2.0 mmol) and anhydrous
potassium carbonate (276 mg, 2 mmol) were added to an
anhydrous acetone (15 mL) solution of N-(adamantan-1-
yl)morpholine-4-carbothioamide (560 mg, 2 mmol) and the
mixture was heated under reflux for 4 h. The solvent was
then distilled off in vacuo and the residue was washed
with water (20 mL), dried and crystallized from ethanol
to yield 380 mg (85%) of the title compound as colour-
less crystals. M. pt.: 371–373 K. Single crystals suitable for
X-ray analysis were obtained by the slow evaporation of a
CHCl3/EtOH (v:v) solution of the compound held at room tem-
perature. 1H NMR (CDCl3, 700.17 MHz): δ [p.p.m.] 1.63–1.69
(m, 6H, adamantane-H), 1.84 (m, 6H, adamantane-H), 2.01
(s, 3H, adamantane-H), 3.25–3.30 (m, 4H, morpholine-H),
3.69–3.74 (m, 4H, morpholine-H), 3.91 (s, 2H, benzylic-CH2),
7.17 (d, 2H, Ar—H, J= 7.5 Hz), 7.45 (d, 2H, Ar—H, J= 7.5 Hz).
13C{1H} NMR (CDCl3, 176.08 MHz): δ [p.p.m.] 29.59, 29.94,
36.57, 54.69 (adamantane-C), 37.76 (benzylic-CH2), 49.70, 66.85
(morpholine-C), 121.00, 130.51, 137.26, 146.91 (Ar—C), 156.46
(C=N). ESI-MS,m/z (Rel. Int.): 449.4 [M+ 2+H, 100]+, 451.4
[M+ 2+H, 98]+.
Experimental details
The C-bound H atoms were geometrically placed (C—H=
0.93–0.98 Å) and refined as riding with U iso(H)= 1.2Ueq(C).
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Table 2: Fractional atomic coordinates and isotropic or equivalent
isotropic displacement parameters (Å2).
Atom x y z Uiso*/Ueq
Br1 1.20216(3) 0.36045(2) 0.54756(2) 0.02552(6)
S1 0.55468(6) 0.14208(4) 0.28378(3) 0.01351(9)
O1 1.14454(17) 0.01989(12) 0.07956(9) 0.0182(3)
N1 0.87498(18) 0.15584(14) 0.17322(9) 0.0113(3)
N2 0.73859(18) 0.36611(14) 0.16104(9) 0.0118(3)
C1 0.7319(2) 0.23870(16) 0.19672(11) 0.0108(3)
C2 0.7038(2) 0.03562(17) 0.36897(12) 0.0163(3)
H2A 0.6252 −0.0259 0.4189 0.020*
H2B 0.7840 −0.0192 0.3380 0.020*
C3 0.8239(2) 0.11681(16) 0.41139(11) 0.0140(3)
C4 1.0159(2) 0.12684(18) 0.38708(12) 0.0161(3)
H4 1.0697 0.0843 0.3435 0.019*
C5 1.1287(2) 0.19982(18) 0.42722(12) 0.0166(3)
H5 1.2571 0.2063 0.4107 0.020*
C6 1.0475(2) 0.26246(17) 0.49185(12) 0.0168(4)
C7 0.8560(3) 0.25542(18) 0.51715(12) 0.0196(4)
H7 0.8027 0.2982 0.5607 0.023*
C8 0.7465(2) 0.18307(18) 0.47583(12) 0.0181(4)
H8 0.6177 0.1786 0.4915 0.022*
C9 1.0376(2) 0.22895(17) 0.11485(12) 0.0146(3)
H9A 1.0759 0.3009 0.1400 0.018*
H9B 1.0053 0.2698 0.0511 0.018*
C10 1.1958(2) 0.12835(18) 0.11499(13) 0.0163(3)
H10A 1.3042 0.1755 0.0767 0.020*
H10B 1.2305 0.0911 0.1787 0.020*
C11 0.9860(2) −0.05104(17) 0.13587(13) 0.0175(4)
H11A 1.0193 −0.0918 0.1995 0.021*
H11B 0.9510 −0.1238 0.1108 0.021*
C12 0.8209(2) 0.04254(17) 0.13826(12) 0.0142(3)
H12A 0.7803 0.0779 0.0756 0.017*
H12B 0.7175 −0.0077 0.1791 0.017*
C13 0.6064(2) 0.46803(16) 0.18183(11) 0.0111(3)
C14 0.5903(2) 0.47399(17) 0.28468(11) 0.0137(3)
H14A 0.5425 0.3879 0.3261 0.016*
H14B 0.7129 0.4895 0.3023 0.016*
C15 0.4107(2) 0.44547(17) 0.15427(12) 0.0139(3)
H15A 0.4202 0.4413 0.0897 0.017*
H15B 0.3600 0.3594 0.1943 0.017*
C16 0.6827(2) 0.60650(16) 0.11913(12) 0.0140(3)
H16A 0.8054 0.6223 0.1367 0.017*
H16B 0.6966 0.6048 0.0540 0.017*
C17 0.4575(2) 0.58975(17) 0.29518(12) 0.0166(4)
H17 0.4466 0.5923 0.3608 0.020*
C18 0.2631(2) 0.56547(18) 0.26744(13) 0.0192(4)
H18A 0.1790 0.6379 0.2751 0.023*
H18B 0.2121 0.4798 0.3080 0.023*
C19 0.2790(2) 0.56173(18) 0.16454(13) 0.0177(4)
H19 0.1549 0.5461 0.1468 0.021*
C20 0.3584(3) 0.69740(18) 0.10043(13) 0.0196(4)
H20A 0.2746 0.7710 0.1059 0.024*
H20B 0.3693 0.6949 0.0355 0.024*
C21 0.5518(2) 0.72245(17) 0.12900(12) 0.0164(4)
H21 0.6027 0.8092 0.0881 0.020*
C22 0.5343(3) 0.72672(17) 0.23178(12) 0.0178(4)
H22A 0.6560 0.7442 0.2497 0.021*
H22B 0.4506 0.7995 0.2390 0.021*
Comment
The highly lipophilic adamantane cage constitutes a core
pharmacophore of several drugs [5]. After the development
of amantadine as efficient anti-viral drug against influenza
A viruses [6] and as anti-parkinsonian drug [7], adaman-
tane derivatives attracted the attention of several drug man-
ufacturers for the development of more potent and safer
bioactive agents. As a result of this intensive search, several
adamantane derivatives were developed and are currently
used as effective therapeutic agents. Among themajor biolog-
ical activities displayed by adamantane based derivatives, the
anti-viral [8], anti-cancer [9], anti-bacterial and anti-fungal
[10], anti-malarial [11] and anti-diabetic [12] activities are the
most important ones. It is also well known that isothiourea
derivatives are of particular value in medicinal chemistry,
exhibiting significant anti-viral [13], anti-cancer [14] and anti-
bacterial [15] activities. The title compound was very recently
prepared among a series of adamantane-isothiourea hybrid
derivatives, which displayed marked, broad spectrum anti-
bacterial activity [16].
The molecule [systematic name: 4-bromophenyl]
methyl-N-(tricyclo[3.3.1.13,7]decan-1-yl)morpholine-4-carbox-
imidothioate] is shown in the figure (70% displacement ellip-
soids) and is constructed about a planar CN2S chromophore
with the r.m.s. deviation of the C1, N1, N2 and S1 atoms being
0.008 Å. The configuration about the C1=N2bond [1.262(2) Å]
is Z, and the conformation of the morpholinyl ring is that of
a chair. The bromobenzyl group is orientated to lie over the
remainingpart of themolecule but is slightly inclined towards
the morpholinyl group with the C2—S1—C1—N1 torsion angle
being 46.80(13)° compared with the C2—S1—C1—N2 torsion
angle of−130.63(15)°.
With the exception of weak π—π stacking between cen-
trosymmetrically related molecules [inter-centroid Cg(C3—
C8)· · ·Cg(C3—C8)i distance= 3.8802(11) Å for symmetry
operation i: 2 – x,− y, 1− z], the molecular packing is devoid
of directional interactions. This observation is highlighted by
the high contribution to the calculated Hirshfeld surface by
H· · ·H contacts, that is 68.5% [17, 18]. The next highest contri-
bution to surface of 14.0% is due to Br· · ·H/H· · ·Br contacts
but, none of these occur within the sum of the respective van
der Waals radii.
The structure of the present compound has two liter-
ature precedents, that is with 4-nitrobenzyl [16] and 3,5-
trifluorobenzyl [19] groups. The superimposition of the
three molecules reveals a very high degree of concordance
in the molecular structures with any minor variations in
conformation being associated only with the relative orien-
tations of the substituted benzyl groups. Bond lengths and
other geometric parameters are in the expected ranges for
such a compound [20].
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